Evidence map›Paper›PMID 35138759›Full record

ArticleNederlands tijdschrift voor geneeskunde2022

[From promising biomarker to useful test: a long and winding road].

Patrick M Bossuyt

Abstract readComment
PubMed
In one paragraph

Article in Nederlands tijdschrift voor geneeskunde, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Patrick M BossuytAmsterdam UMC, locatie AMC, afd. Epidemiology & Data Science, Amsterdam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The past few years have seen a tremendous acceleration in research on biomarkers. The vast majority of published research papers conclude with positive conclusions: gains are to be expected, improved outcomes for the patient and a more efficient and cheaper care process. Unfortunately, these promises are not always fulfilled. In this commentary, we discuss a recently proposed biomarker for impending pre-eclampsia: placental growth factor. Mean values of that marker have been shown to differ between women who developed pre-eclampsia and those who did not. Yet a randomized trial, published this year, showed that deploying that marker in clinical management did not improve maternal or neonatal outcomes. We discuss possible explanations and look forward to further research.

Indexed as

Pre-EclampsiaBiomarkersFemaleHumansInfant, NewbornPlacenta Growth FactorPregnancyBiomarkersPlacenta Growth Factor

Identifiers

PMID35138759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.